'Selective' COX-1 or COX-2 NSAIDs: time to change a misleading measure

The ongoing important debate about the relative benefits/risks of COX‐1 or COX‐2 NSAIDs is hampered by the use of a measure of ‘selectivity’ that is inherently flawed. An alternative measure provides more meaningful and clinically relevant information.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacy and therapeutics 2014-10, Vol.39 (5), p.455-456
Hauptverfasser:	Raffa, R. B., Gudin, J. A., Nalamachu, S., Pergolizzi Jr, J. V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics Confounding Factors (Epidemiology) Cyclooxygenase 1 - metabolism Cyclooxygenase 2 Inhibitors - metabolism Cyclooxygenase Inhibitors - metabolism Humans Inhibitory Concentration 50
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The ongoing important debate about the relative benefits/risks of COX‐1 or COX‐2 NSAIDs is hampered by the use of a measure of ‘selectivity’ that is inherently flawed. An alternative measure provides more meaningful and clinically relevant information.
ISSN:	0269-4727 1365-2710
DOI:	10.1111/jcpt.12192